256 related articles for article (PubMed ID: 23939688)
1. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review).
Piva R; Spandidos DA; Gambari R
Int J Oncol; 2013 Oct; 43(4):985-94. PubMed ID: 23939688
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer.
Radojicic J; Zaravinos A; Vrekoussis T; Kafousi M; Spandidos DA; Stathopoulos EN
Cell Cycle; 2011 Feb; 10(3):507-17. PubMed ID: 21270527
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer.
Zhao Z; Li L; Du P; Ma L; Zhang W; Zheng L; Lan B; Zhang B; Ma F; Xu B; Zhan Q; Song Y
Theranostics; 2019; 9(5):1401-1416. PubMed ID: 30867840
[No Abstract] [Full Text] [Related]
5. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA regulation of progesterone receptor in breast cancer.
Gilam A; Shai A; Ashkenazi I; Sarid LA; Drobot A; Bickel A; Shomron N
Oncotarget; 2017 Apr; 8(16):25963-25976. PubMed ID: 28404930
[TBL] [Abstract][Full Text] [Related]
7. miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.
Liu F; Zhuang L; Wu R; Li D
J BUON; 2019; 24(5):1905-1912. PubMed ID: 31786854
[TBL] [Abstract][Full Text] [Related]
8. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
10. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
Sakurai M; Masuda M; Miki Y; Hirakawa H; Suzuki T; Sasano H
Int J Biol Markers; 2015 May; 30(2):e190-9. PubMed ID: 25907662
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis.
Liu X; Gu X; Sun L; Flowers AB; Rademaker AW; Zhou Y; Kiyokawa H
BMC Cancer; 2014 Feb; 14():57. PubMed ID: 24485087
[TBL] [Abstract][Full Text] [Related]
13. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
14. Non-Specific Blocking of miR-17-5p Guide Strand in Triple Negative Breast Cancer Cells by Amplifying Passenger Strand Activity.
Jin YY; Andrade J; Wickstrom E
PLoS One; 2015; 10(12):e0142574. PubMed ID: 26629823
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs-mediated cell fate in triple negative breast cancers.
Sui X; Wang X; Han W; Li D; Xu Y; Lou F; Zhou J; Gu X; Zhu J; Zhang C; Pan H
Cancer Lett; 2015 May; 361(1):8-12. PubMed ID: 25748387
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
17. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development.
Jin C; Yan B; Lu Q; Lin Y; Ma L
Tumour Biol; 2016 Jun; 37(6):7383-94. PubMed ID: 26676637
[TBL] [Abstract][Full Text] [Related]
19. Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.
Bottai G; Diao L; Baggerly KA; Paladini L; Győrffy B; Raschioni C; Pusztai L; Calin GA; Santarpia L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106823
[TBL] [Abstract][Full Text] [Related]
20. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.
Nassar FJ; El Sabban M; Zgheib NK; Tfayli A; Boulos F; Jabbour M; El Saghir NS; Talhouk R; Bazarbachi A; Calin GA; Nasr R
PLoS One; 2014; 9(9):e107566. PubMed ID: 25232827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]